Psychedelic Spotlight News

  • MindMed Management Update & Earnings Call [ MMED / MNMD / MMQ]

    Here’s MindMed’s (MMED / MNMD / MMQ) Q1 2021 recorded Earnings call! Soon we will upload a video detailing all the highlights but for now, for those who are interested in listening to the entire call, you can listen to it here!

    Enjoy!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MindMedNews #MNMD

  • New Players, New Studies & Financial Results [MindMed, CMPS, NUMI, TRUFF & WESA]

    Researchers personally trying MDMA, a new company on the block, financial results for MindMed (MMED / MNMD / MMQ) & Compass Pathways (CMPS) & news on Numinus Wellness (NUMI) & Red Lights Holland (TRIP/TRUFF), this is what we will be covering in today’s episode.

    Timestamps:
    0:00 – Intro
    0:18 – FDA clears researchers to test MDMA on themselves
    1:55 – MindMed (MMED / MNMD) announces Q1 Financials
    4:30 – Compass Pathways (CMPS) announces Q1 Financials
    6:56 – Numinus Wellness (NUMI) supplies psilocybin extract to Optimi Health
    8:17 – Red Light Holland (TRIP / TRUFF) has a new app called ‘iMicro’
    9:31 – Wesana Health Holdings (WESA) begins trading on the CSE

    Link to the FDA clearing researchers to test MDMA on themselves:
    https://www.marijuanamoment.net/fda-clears-researchers-to-study-mdma-use-by-therapists-being-trained-in-psychedelic-medicine/

    Link to Mindmed’s Q1 2021 Financial report and business highlights:
    https://www.newswire.ca/news-releases/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline-816112809.html

    Link to Compass Pathways (CMPS) Q1 Financial report:https://www.globenewswire.com/news-release/2021/05/13/2228969/0/en/COMPASS-Pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021.html

    Link to Numinus (NUMI) supplying psilocybin extract to Optimi Health:
    https://psilocybinalpha.com/news/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application

    Link to Red Light Holland’s (TRIP / TRUFF) new app ‘iMicro’:
    https://investingnews.com/news/agriculture-investing/red-light-holland-imicro-digital-care-app-and-telecounseling-goes-live/

    Link to Wesana Health Holdings (WESA):
    https://psilocybinalpha.com/news/wesana-health-commences-trading-on-the-cse

    Image source: https://www.google.com/search?q=mike+tyson&rlz=1C1CHBF_enCA821CA821&sxsrf=ALeKk01FAUv0g0uK0yvLRLlkKOCgPEda6g:1621187634437&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiagcLI4s7wAhWSF1kFHUeECgsQ_AUoAnoECAEQBA&biw=1600&bih=699#imgrc=Hwv5W22HvZQ3QM

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    editing by: @themyaholy
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #CMPS

  • How Clinical Trials Work and Who is WINNING the Race (FOR NOW) // MAPS, CMPS, MNMD & more

    Who’s winning the psychedelics race and how do clinical trials work? This topic has been requested a lot lately so we decided to give you a rundown on the clinical trials system and the psychedelic-inspired companies who are furthest advanced at the moment. Of course, for now, MAPS is leading the race. However, other public companies such as Compass Pathways (CMPS) and MindMed (MMED / MNMD) are not far behind, for now.

    Hopefully, this introductory video will help some new retail investors who are considering investing in biotech companies who do not te have an approved drug, to understand the importance that clinical trials need to play in their investing decisions.

    Timestamps:
    0:00 – Intro
    1:34 – What is the clinical trial system?
    2:15 – Preclinical
    3:00 – Phase 0
    3:32 – Phase I
    5:45 – Phase II
    8:26 – Phase III
    10:28 – Phase IV
    11:08 – Who’s winning the race?
    11:16 – MAPS ( non-for-profit entity): Has already completed a Phase III study on MDMA to treat PTSD
    12:02 – Compass Pathways (CMPS) has a Phase IIb trial to treat TRD with COMP360
    12:28 – MindMed (MMED / MNMD) has completed a Phase IIa LSD study to treat Anxiety and will begin phase IIb this year. MindMed also has other Phase II studies involving LSD & Ibogaine (18-MC)
    13:23 – Mydecine (MYCO) and CYBIN (CYBN) following suit

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    editing by: @themyaholy
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #Numi #CMPS